Lung Cancer
Current Clinical Trials
Curie Research by Curie Oncology
Clinical Trial – Lung Cancer
| Protocol Name / No. | Protocol Title | Principal Investigator |
|---|---|---|
| SOHO-02 | A phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate efficacy and safety of BAY 2927088 in comparison with SOC as a first-line therapy in patients with unresectable, locally advanced or metastatic NSCLC with HER2 activating mutations NCT number: https://clinicaltrials.gov/study/NCT06452277 | Dr Toh Chee Keong |
| KRYSTAL7 | A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) NCT number: https://clinicaltrials.gov/study/NCT04613596 | Dr Toh Chee Keong |
| FURMO-006 | A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA) NCT number: https://clinicaltrials.gov/study/NCT07185997 | Dr Toh Chee Keong |